StockNow
Log in
U.S. Markets

Biotech company Enveda announced this week that its experimental drug, designed to curb appetite and mimic some of the body’s effects of physical activity, delivered encouraging results in its first clinical trial, NYP reports

StockNow breaking-news AI analysis

Enveda progressed its oral drug candidate ENV-308 into Phase 1 clinical trials for chronic weight management and muscle preservation.

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Yemeni Armed Forces announce it will issue an important statement at 16:00 local time (14:00BST/09:00EDT) regarding the targeting of Saudi Mercaneries with the Rajum drone

U.S. Markets

Nvidia (NVDA) is in advanced discussions to make an investment in Cloverleaf Infrastructure, WSJ reports, citing sources; expected to invest several hundred million dollars; announcement expected as soon as Friday

NVDAGeopolitics

[MARKET UPDATE]: Crude slides with stocks and bonds gaining as Pezeshkian comments get wider airing; "Iran should end war now that it is in a position of strength"